Abstract
Background Disengagement from antiretroviral therapy (ART) is highest in the early treatment period (≤6 months after initiation/re-initiation), but low intensity models designed to increase retention generally exclude these clients. We describe client preferences for HIV service delivery in the early treatment period.
Methods From 9/2022-6/2023, we surveyed adult clients who were initiating or on ART for ≤6 months at primary health facilities in South Africa and Zambia. We collected data on experiences with and preferences for HIV treatment.
Results We enrolled 1,098 participants in South Africa (72% female, median age 33) and 771 in Zambia (67% female, median age 32), 38% and 34% of whom were initiating/re-initiating ART in each country, respectively. While clients expressed varied preferences, most participants (94% in South Africa, 87% in Zambia) were not offered choices regarding service delivery. 82% of participants in South Africa and 36% in Zambia reported receiving a 1-month supply of medication at their most recent visit; however, South African participants preferred 2- or 3-month dispensing (69%), while Zambian participants preferred 3-or 6-month dispensing (85%). Many South African participants (65%) would prefer to collect medication in community settings, while Zambian participants (70%) preferred clinic-based collection. Half of participants desired more one-on-one counselling and health information. Most participants reported positive experiences with providers, but long waiting queues were reported by South African participants.
Conclusions During the first six months on ART, many clients would prefer less frequent clinic visits, longer dispensing intervals, and frequent, high-quality counselling. Care models for the early treatment period should reflect these preferences.
Registration Clinicaltrials.gov NCT05454839, Clinicaltrials.gov NCT05454852
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://gatesopenresearch.org/articles/7-119
Funding Statement
Funding for the study was provided the Bill & Melinda Gates Foundation through award INV-031690. The funder had no role in study design, data collection, analysis, or preparation of this manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Country specific protocols for the PREFER study were approved by Boston University Institutional Review Board under protocol H42726 (PREFER South Africa) and H42903 (PREFER Zambia). Both protocols were also approved by the University of Witwatersrand Human Research Ethics Committee under protocols M220440 (PREFER South Africa) and M210342 (PREFER Zambia). In addition, the protocol for South Africa was approved by the Provincial Health and Research Committees through the National Health Research Database for each study district. The Zambia protocol was also approved by national ethics governing boards, the ERES Converge IRB (2022 June 007), and the Zambia National Health Research Authority (NHRA000007 10 07 2022).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data used in the present study are available upon reasonable request to the authors and will be posted in a public repository following the closing of the ethics protocol.
